Allarity reports Phase 2 data for stenoparib in advanced ovarian cancer; durable benefit in platinum-resistant patients

Allarity Therapeutics, Inc.

5 of 15 patients stayed on therapy >4 months; 1 had confirmed complete response lasting >10 months.
2 patients remain on therapy >17 months; patient with primary platinum-refractory disease remained >40 weeks.
Stenoparib well-tolerated with no bone marrow toxicity typical of first-generation PARP inhibitors.
Clinical benefit seen in BRCA wild-type patients, supporting dual PARP/Wnt pathway inhibition.
New Phase 2 protocol announced focusing on platinum-resistant patients with single prior chemo line.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.